Kenvue Stock News

Texas Attorney General Ken Paxton on Thursday asked a state judge to block Kenvue from paying a nearly $400 million shareholder dividend this month, after suing the drugmaker for allegedly concealing risks to children from the use of Tylenol by pregnant women.

No single month beats November for S&P 500 stock market performance. And a handful of stocks are already taking off.

Enbridge has a low-risk business that pays a steady and growing dividend. Kenvue's pending acquisition by Kimberly-Clark creates a great opportunity for income investors.

Fiserv (FI) leads decliners with a 49% drop, driven by leadership turmoil, weak consumer spending, and a downgraded quant rating to 'Strong Sell.' Alexandria Real Estate (ARE) and Robert Half (RHI) suffer from sector-specific headwinds, with ARE hurt by biotech weakness and RHI by declining revenue and a negative outlook. Molina Healthcare (MOH) and Baxter (BAX) face earnings cuts and operation...

Kimberly-Clark is merging with Kenvue. The deal brings together two companies with long histories of growing their dividends.

Mike Hsu aims to stoke the consumer company's growth by veering into Kenvue's higher-margin but risky health products.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Kenvue Inc. (NYSE: KVUE) to Kimberly-Clark Corporation (NasdaqGS: KMB). Under the terms of the proposed transaction, shareholders of Kenvue will receive $3.50 in cash plus 0.14625 Kimberly-Clark sh...

Kimberly-Clark CEO Mike Hsu told CNBC's Jim Cramer that his company's acquisition of Tylenol maker Kenvue will create value for shareholders, even as the the pain reliever is scrutinized by the Trump administration. Hsu said Tylenol sales haven't been majorly impacted by Secretary of Health and Human Services Robert F.